Home › Burkitt Lymphoma › Texas › Corpus Christi
Burkitt Lymphoma clinical trials in Corpus Christi, TX
4 studies for Burkitt Lymphoma are looking for participants at sites in and around Corpus Christi (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Driscoll Children's Hospital, Corpus Christi
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Driscoll Children's Hospital, Corpus Christi
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Driscoll Children's Hospital, Corpus Christi
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Driscoll Children's Hospital, Corpus Christi
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL13 studies
- Cincinnati, OH12 studies
- Seattle, WA12 studies
- Atlanta, GA11 studies
- Boston, MA10 studies
- Los Angeles, CA10 studies
- Durham, NC10 studies
- Aurora, CO10 studies
Other studies in Corpus Christi
- Obesity6 studies
- Overweight5 studies
- Type 2 Diabetes4 studies
- Steatotic Liver Disease3 studies
- Acute Biphenotypic Leukemia3 studies
- Acute Myeloid Leukemia3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.